Navigation Links
Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.
Date:11/2/2009

CINCINNATI, Nov. 2 /PRNewswire/ -- Prasco Laboratories announced today that it has entered into agreements with Winthrop U.S., a business of sanofi-aventis U.S., to provide sales support and distribution services to Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release tablets and Drisdol® (ergocalciferol) capsules in the United States under the Winthrop label. Fexofenadine HCl and pseudoephredrine HCl extended-release tablets and ergocalciferol capsules represent the first two products launched in the U.S. by Winthrop U.S. under the Winthrop label with Prasco providing sales support and distribution services to Winthrop U.S. Prasco expects to begin shipping the products immediately. Specific financial terms of the agreements were not disclosed.

"We are especially proud to expand our relationship with sanofi-aventis U.S., and we are certainly pleased to provide pharmacists and consumers with these authorized generic options," said Prasco Chief Executive Officer E. Thomas Arington. "Consumers and pharmacists can have confidence in their prescription drug choices, when they have the identical product, quality, reliability of supply and the identical experience that only the brand can provide."

ALLEGRA-D and DRISDOL are registered trademarks of sanofi-aventis.

About Prasco

Prasco provides patients, pharmacists and customers with generic options that deliver the identical brand experience. The company's business model encourages competition and benefits consumers through significant cost savings.

Prasco sells its product line through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers. Prasco operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and warehouse facility including DEA-approved facilities for Schedule II-V controlled drug products. For more information, visit www.prasco.com.

SOURCE Prasco Laboratories


'/>"/>
SOURCE Prasco Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Accurays Treatment Planning Service Active at 20 Percent of U.S. CyberKnife Centers
2. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
3. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
4. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
5. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
6. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
7. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
8. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
9. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
10. Clinical Logistics Enters Partnership with Gentris Corporation
11. Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Interpace Diagnostics Group, ... a fully integrated commercial company that provides clinically ... announced that it has entered into agreements to ... RedPath Shareholders ("RedPath") and concurrently terminate its royalty ... outstanding secured debt to RedPath amounting to $9.34 ...
(Date:3/23/2017)... -- Drug diversion is a significant contributing factor in ... new oral fluid monitoring test, announced today by ... detailed and actionable information to clinicians than urine ... patient safety, and help to identify drug diversion. ... Evaluation (CORE) system is the first patient-monitoring screening ...
(Date:3/23/2017)... VANCOUVER , March 23, 2017 /PRNewswire/ - INVICTUS ... OTC: IVITF; FRA: 8IS) Invictus MD announces that AB ... crops in its licensed production facility under the Access ... Hamilton, Ontario . ... ACMPR in October 2016, is currently operating at half ...
Breaking Medicine Technology:
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... ... 2017 , ... On June 9, 2017, Cassie Springer Ayeni ... in Chicago, Illinois. She will present on: , Filing Benefit Claims—Responding to ... involve claims for long-term disability benefits. This session will address the first ...
(Date:3/24/2017)... ... 24, 2017 , ... Judy Buchanan, co-owner of Serenity Natural ... Judy says, “I am passionate about sharing Reiki as a holistic, complementary therapy ... challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about ... as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is ... for writing, especially about truth and human behavior. , Published by Christian Faith Publishing, ...
(Date:3/23/2017)... ... 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce ... The clinic is the group’s second in New Braunfels and 22nd in Texas. , ... Braunfels location brings things full circle for the group, “It’s crazy to think that ...
Breaking Medicine News(10 mins):